Research carried out in collaboration with the University of Birmingham in the UK has shown a combination low-cost pill called a polypill containing four drugs is effective in preventing cardiovascular disease.
The results of the clinical trial, published in The Lancet, demonstrate for the first time the effectiveness of a fixed-dose combination pill for preventing cardiovascular disease (heart disease and stroke) and indicate that the benefits of widespread polypill use outweigh any known side effects.
Overall, compared with lifestyle advice, taking the polypill reduced the risk of major cardiovascular events by 34%, and by around 40% in individuals without a history of cardiovascular disease and by approximately 20% in those with previous cardiovascular disease. The effects were similar in both men and women. After adjusting for participants taking other cardiovascular drugs, the overall protective effect of the polypill was reduced to 22% (from 34%) but remained statistically significant.
Systolic and diastolic blood pressure did not differ significantly between the groups, but LDL cholesterol was significantly lower in polypill arm.
The findings suggest that 35 individuals would need to be treated with the polypill to prevent one person from having a serious cardiovascular event. In participants with high adherence to treatment and took the polypill as directed at least 70% of the time, the number needed to treat was 21.
The study, led by Tehran University of Medical Sciences in Iran, was designed by Professor Karla Hemming at the University of Birmingham's Instiution of Applied Health Research who also oversaw the statistical analysis of the research findings.
The study included 6,841 people aged 55 years or over living in 236 villages in Northern Iran. Villages were randomly divided into two groups. In 116 villages, 3,417 study participants were given general advice on diet, exercise and smoking. In 120 villages, 3,421 participants were given the same advice on a healthy lifestyle and also a Polypill to take every day.
The Polypill included aspirin, a statin (atorvastatin), and two drugs to lower blood pressure (hydrochlorothiazide and enalapril). After five years, 202 participants in the Polypill villages had suffered from a heart attack or stroke compared to 301 in the villages where only lifestyle advice was given.
Although a few people complained of dizziness, muscle pains or indigestion, these were just as common in people who were taking or not taking the Polypill. The Polypill also seemed to be acceptable, with most people continuing to take it for all five years.
Those who took part in the study were typical middle-aged men and women from the villages. At the start of the study most were aged under 65, one in ten had heart disease, one in ten had diabetes and half had high blood pressure. This suggests that most people of the age group 55-65 years could take the Polypill.
The idea of combining several drugs in a single pill – the Polypill – was originally proposed in 2001. Since then, several small, short-term studies in a number of countries have shown a Polypill could reduce blood pressure and cholesterol levels. But this is the first study large enough to show that a Polypill can prevent heart disease and strokes.
Professor Reza Malekzadeh, of Tehran University of Medical Sciences in Iran, said: “Our research has shown a Polypill prevents heart disease in a developing country and is an important step forward in preventing heart disease.”
Professor KK Cheng, Director of the Institute of Applied Health Research at the University of Birmingham, added: “A Polypill strategy could also work in other countries, particularly those where cardiovascular diseases are still increasing.”
Professor Tom Marshall, also of the University of Birmingham who is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) West Midlands, said: “Because they have the most to gain, the most efficient strategy would be to offer the Polypill to those at highest risk of heart disease.”
Professor Neil Thomas, also of the University of Birmingham, added: “Previously there had been concerns as to whether a Polypill would be effective in those who had not already had cardiovascular disease, but this study shows that in high-risk populations as in Iran this approach is effective in preventing first and subsequent cardiovascular disease”.
The research was carried out in a collaboration between the University of Birmingham, Tehran University of Medical Sciences in Iran, Golestan University of Medical Sciences in Iran, Morgan State University in the USA, Isfahan University of Medical Sciences in Iran, Icahn School of Medicine in the USA and the National Cancer Institute in the USA.
For more information or to arrange interviews please contact Emma McKinney, Communications Manager (Health Sciences), University of Birmingham, call +44 (0) 121 414 6681, or contact the press office on +44 (0) 7789 921 165.
- The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 6,500 international students from over 150 countries.
- Roshandel et al (2019). ‘A pragmatic cluster randomized controlled trial of the effectiveness of polypill for primary and secondary prevention of cardiovascular diseases: results from the PolyIran trial’. The Lancet.
- The research was funded by Tehran University of Medical Sciences, Barakat Foundation, and Alborz Darou.
- The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:
- Funds, supports and delivers high quality research that benefits the NHS, public health and social care
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
- The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government.